id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-321085-u0pl323l	Kumar, Karan	Elevated Liver Chemistries in COVID-19—Is It Not a Concern?	2020-09-14		.txt	text/plain	607	44	54	The authors have shown that around 28% of patients with COVID-19 have deranged liver function tests (LFTs) at admission, and furthermore, 32% of patients developed elevated liver chemistries during illness. Another interesting observation made in this study was that deranged LFT has no impact on the outcome of COVID-19 patients. In the recent meta-analysis comprising 107 studies, it has been shown that nonsurvivors and severely infected COVID-19 patients had a higher risk of presenting with a deranged LFT. Elevated liver chemistries also aid in predicting the outcomes of COVID-19, which is in contrast to the observation made in the current study (3, 4) . Despite this correlation in the current study, patients with deranged LFTs had no difference in outcomes. The authors have reported that COVID-19 patients with pre-existing CLD had outcomes similar to those without preexisting CLD, which is in congruence with the observation made in the recently published meta-analysis.	./cache/cord-321085-u0pl323l.txt	./txt/cord-321085-u0pl323l.txt